Coronavirus

CDC expands recommended timeline between second and third COVID-19 vaccine to 8 weeks for people 12 years and older, especially for young men, to reduce the risk of myocarditis.

Infection-acquired immunity to SARS-CoV-2 remains higher for longer when followed by vaccination.

The companies plan to seek regulatory authorization for the vaccine both in the US and Europe.

The IDSA, HIVMA, and SHEA released a statement opposing legal intervention on behalf of ivermectin as a COVID-19 treatment.

A clinician offers his perspective on how the virus is behaving and the role that vaccines and therapies will play.

COVID-19 patients’ ZIP codes influenced how sick they were upon hospitalization, and how much care they needed after admittance.

An Israeli study found COVID-19 reinfection was "relatively rare," and previously infected persons who also received at least 1 dose of the Pfizer-BioNTech mRNA vaccine had an 82% reduced risk of reinfection.

Study highlights elevated levels of antibody response in those with history of COVID-19.

COVID-19 mRNA vaccine effectiveness wanes even faster during Omicron than during Delta variant predominance, but a booster dose still provides lasting defense against COVID-19 hospitalization and death.

A study of patients at high risk of severe COVID-19 disease progression found ivermectin was no more effective than standard care at preventing adverse outcomes.

A preprint study shows the variant is resistant to some monoclonal antibodies and vaccines.

Regular symptom screening revealed completely asymptomatic COVID-19 infection is highly unlikely among unvaccinated people.

As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

The idea of a future with COVID-19 is settling in, and building strategies that improve quality of life as we live with this viral disease are paramount.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.

Convalescent plasma safely raised antibody levels in children at high risk of severe or fatal COVID-19, successfully neutralizing the virus but unlikely to provide lasting protection.

This decision was based from the analysis of the company’s phase 2 BLAZE-4 trial.

Pfizer-BioNTech previously asked for FDA approval to administer its COVID-19 vaccine in children 6 months-4 years of age, but has deferred the request after reviewing more data.

Their investigational vaccine, NVX-CoV2373, demonstrated 82% efficacy against the Delta variant in participants 12-17 years old.

A study looked at COVID-19 vaccination rates and new COVID-19 infections across US counties during the Delta surge last summer. Many of the highly infected counties were considered rural, highlighting some of the vaccination challenges surrounding these areas.

COVID-19 vaccination rates were higher in counties with more primary care physicians, suggesting doctors are in unique positions of trust with their patients and can encourage vaccination.

32% of older adults had 1 or more new, persistent clinical conditions after COVID-19 infection.

Trying to increase COVID-19 vaccination rates in these populations has been challenging. In an attempt to do so, a randomized clinical trial across 133 skilled nursing facilities (SNFs) was performed.

Intranasal COVID-19 vaccines aren’t just needle and pain-free—they may also be more effective at protecting against current and future variants.

Omicron's numerous spike protein mutations caused mass concern, but one research team hypothesizes that its mutations are largely documented and thus susceptible to COVID-19 vaccination.